Tests ITI-1284 for agitation linked to Alzheimer's dementia
Tests ITI-1284 against a placebo in people with agitation from Alzheimer's dementia.
Plain-language title generated from the registry record
Registry title: A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Key facts
- Where
- Grad Zagreb and Zagreb, CroatiaSee the 3 sites
- Phase
- Phase 2
Where in Croatia
- Clinic for psychiatry Sveti IvanGrad Zagreb, CroatiaTaking people
- Klinika za psihijatriju VrapceGrad Zagreb, CroatiaTaking people
- University Hospital Centre ZagrebZagreb, CroatiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Intra-Cellular Therapies, Inc.
- Trial code
- NCT06651567EU 2024-514680-26-00
- Record updated
- 3 November 2026
- Original description
This is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer's dementia.Read full original descriptionShow less
A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study of the Efficacy, Safety, and Tolerability of ITI-1284 in Patients With Agitation Associated With Alzheimer's Dementia
This is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer's dementia.
Inclusion: Can understand the nature of the trial and protocol requirements and provide signed informed consent, if in the judgement of the Investigator is deemed competent to provide consent or if patient is deemed not competent to provide informed consent, with the patient's assent (if capable), consent may be provided by an appropriate person (eg, patient's Legally Authorized Representative [LAR]) before the initiation of any study-specific procedures in accordance with local regulations; Meets clinical criteria for Alzheimer's disease based on 2011 National Institute of Aging-Alzheimer's Association (NIA-AA) dementia criteria and biomarker criteria and either:; Has a high likelihood for amyloid pathology consistent with Alzheimer's disease, as confirmed by blood-based biomarker at Screening as detected by an appropriately validated test; or; Has historical documentation of cerebrospinal fluid (CSF) biomarker or amyloid positron emission tomography (PET) brain scan; Meets all criteria for agitation according to the International Psychogeriatric Association (IPA) consensus definition; Has clinically meaningful agitation defined as a Neuropsychiatric Inventory-Agitation/Aggression (NPI-AA) domain total score of ≥ 4 at both Screening and Baseline; CGI-S score ≥ 4 at Screening and Baseline; Has Mini-Mental State Examination, 2nd Edition™: Standard Version (MMSE-2®:SV) score of 6 to 24 at Screening.
Exclusion: Agitation symptoms are attributable to concomitant medications, adverse environmental conditions, substance abuse, or active medical or psychiatric conditions as per Investigator's judgment; Has been diagnosed with one or more of the following psychiatric conditions:; Schizophrenia, schizoaffective disorder, or other psychotic disorder that is not related to Alzheimer's dementia; Bipolar disorder; Major depressive disorder, unless it is considered stable and treated for at least 8 weeks prior to Screening; Has a significant risk for suicidal behavior during the course of their participation in the study, or is considered to be an imminent danger to themselves or others, in the opinion of the investigator, and/or as assessed by Columbia Suicide Severity Rating Scale (C-SSRS); or the patient has had 1 or more suicide attempts within the 2 years prior to Screening; The patient has known hypersensitivity or intolerance to ITI-1284 or lumateperone, or to any of their excipients.